Filtered By:
Management: Medicare
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 238 results found since Jan 2013.
ACOs score slight bump in bonus payments
Accountable care organizations participating in the Medicare Shared Savings Program generated $466 million in savings in 2015, up from $411 million in 2014, the Centers for Medicare & Medicaid Services announced.
Despite the growth in savings, there was little growth in the number of ACOs...
Source: Skin and Allergy News - September 7, 2016 Category: Dermatology Source Type: news
CMS offers lower-stress reporting options for MACRA in 2017
Physicians will have four options for when they can start meeting the requirements for the Merit-based Incentive Payment System (MIPS) track under regulations that implement the Medicare Access and CHIP Reauthorization Act.
The options are designed to allow physicians a variety of ways to get...
Source: Skin and Allergy News - September 8, 2016 Category: Dermatology Source Type: news
Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis
Discussion
Findings from this observational study of patients with RA suggested that anti-TNF biologics may be associated with higher AMI risk compared with abatacept.
Source: Annals of the Rheumatic Diseases - September 8, 2016 Category: Rheumatology Authors: Zhang, J., Xie, F., Yun, H., Chen, L., Muntner, P., Levitan, E. B., Safford, M. M., Kent, S. T., Osterman, M. T., Lewis, J. D., Saag, K., Singh, J. A., Curtis, J. R. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research
EpiPen cost increases far exceed overall medical inflation
Total Medicare part D spending on EpiPen auto-injectors rose from $7.0 million in 2007 to $87.9 million in 2014 – an increase of 1,151%, according to an analysis released Sept. 20 by the Kaiser Family Foundation.
The number of EpiPen users also increased over that time, however, bringing with it...
Source: Skin and Allergy News - September 22, 2016 Category: Dermatology Source Type: news
Legislators: Investigate Medicare fraud before paying doctors
Republican leaders in Congress are calling on CMS to impose stricter safeguards against fraudulent Medicare billing by physicians.
The chairmen of the Senate Finance Committee, the House Ways and Means and Energy and Commerce Committees, and the chairmen of key House subcommittees said that the...
Source: Skin and Allergy News - September 22, 2016 Category: Dermatology Source Type: news
The 10 Health Benefits Of Dogs (And One Health Risk)
1. Improve heart health
Dogs don’t just fill your heart; they actually make it stronger. Studies show that having a canine companion is linked to lower blood pressure, reduced cholesterol, and decreased triglyceride levels, which contribute to better overall cardiovascular health and fewer heart attacks. What’s more, dog owners who do have heart attacks have better survival rates following the events.
2. Keep you fit and active
Health experts recommend that adults get about 2 hours and 30 minutes worth of moderate exercise per week. Dog owners are way more likely to hit that goal. “People love to be outs...
Source: Healthy Living - The Huffington Post - September 23, 2016 Category: Consumer Health News Source Type: news
Medical Errors Should Not Be Our 3rd Leading Cause of Death
Suppose two jumbo jets crashed every day, killing a total of about 365,000 people in a year. Remarkably enough that's about the level of carnage caused every year in our country by avoidable medical mistakes.
We would never tolerate such an incredible loss of life were it caused by recurring plane crashes (or most anything else). The Federal Aviation Authority would be given immediate and unlimited funding to figure out exactly why the planes were crashing and to do whatever it takes to make them safe again.
In fact, complete reporting of mistakes, and constantly correcting them, has made flying in a commercial plane abo...
Source: Science - The Huffington Post - September 27, 2016 Category: Science Source Type: news
Costly Care for Surgical Complications Tied to Worse Outcomes Costly Care for Surgical Complications Tied to Worse Outcomes
More cost-efficient care for surgical complications was tied to better outcomes in an analysis of Medicare claims data.Medscape Medical News
Source: Medscape Allergy Headlines - October 6, 2016 Category: Allergy & Immunology Tags: General Surgery News Source Type: news
EpiPen price hike cost Pentagon millions
Mylan Pharmaceuticals‘ (NSDQ:MYL) 500% price increase on its epinephrine auto-injector cost the U.S Defense Dept. millions, according to data provided to Reuters.
The Pentagon spent $57 million on Mylan’s EpiPen last year, up from $9 million in 2008, largely driven by volume and price hikes that affected prescriptions filled at retail pharmacies. Although the Pentagon gets a government discount for EpiPens from military treatment facilities and by mail order, nearly half of its spending was at retail pharmacies. Recently, it paid an average of $528 for a two-pack of the lifesaving allergy treatment. That&...
Source: Mass Device - October 31, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Centers for Medicare and Medicaid Services (CMS) Mylan Source Type: news
CMS acting chief Slavitt slams drug pricing
Centers for Medicare & Medicaid Services acting chief Andy Slavitt admonished pharma companies like Mylan (NSDQ:MYL) over unsustainable price increases before the Biopharma Congress in Washington D.C. last week.
Mylan came under fire this year after reports showed that the Canonsburg, Penn.-based company raised the price of its emergency allergy epinephrine injector by 500% since it acquired the product in 2007 from Merck. CEO Heather Bresch pledged to expand the company’s patient assistance program and launch a generic device that will cost $300, half of what a 2-pack of EpiPens costs.
Get the full story ...
Source: Mass Device - November 7, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Healthcare Reform Pharmaceuticals Wall Street Beat Centers for Medicare and Medicaid Services (CMS) Mylan Teva Pharmaceuticals Source Type: news
U.S. Watchdog Told Medicare, Medicaid That EpiPen Was Misclassified in 2009 -Senator U.S. Watchdog Told Medicare, Medicaid That EpiPen Was Misclassified in 2009 -Senator
The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV ' s EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said Tuesday.Reuters Health Information
Source: Medscape Allergy Headlines - November 9, 2016 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news
Partisan Jousting Marks Price Hearing for HHS Post
(MedPage Today) -- Medicaid, Medicare and ACA Repeal debated during nominee hearing
Source: MedPage Today Allergy - January 25, 2017 Category: Allergy & Immunology Source Type: news
CMS nominee Verma: Mylan ’ s EpiPen case ‘ disturbing ’
Seema Verma, the nominee to head the Centers for Medicare & Medicaid, said at her confirmation hearing that she would like to review the way pharmaceutical companies classify products as generic or branded, citing the case of Mylan‘s (NSDQ:MYL) EpiPen emergency allergy device.
Mylan faced criticism this year for classifying EpiPen as a generic and paying smaller rebates to Medicaid than if the device was listed as branded.
Get the full story at our sister site, Drug Delivery Business News.
The post CMS nominee Verma: Mylan’s EpiPen case ‘disturbing’ appeared first on MassDevice.
Source: Mass Device - February 17, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Healthcare Reform Pharmaceuticals Wall Street Beat Centers for Medicare and Medicaid Services (CMS) Mylan Source Type: news
Trump's Pick To Lead Health Agency Calls EpiPen Issue 'Disturbing'
U.S. President Donald Trump’s choice to lead an important health agency said on Thursday that the way pharmaceutical companies classify products as generic or branded needs to be reviewed in order to help hold down government spending, as she cited Mylan NV’s EpiPen emergency allergy treatment.
Seema Verma, Trump’s nominee to lead the Centers for Medicare and Medicaid Services (CMS), did not answer questions about whether the U.S. government should negotiate with pharmaceutical companies over drug prices.
“I think what happened with ... the EpiPen issue is very disturbing,” Verma said at her c...
Source: Healthy Living - The Huffington Post - February 17, 2017 Category: Consumer Health News Source Type: news
Variation in outpatient consultant physician fees in Australia by specialty and state and territory.
CONCLUSION: Without data on quality of care in private outpatient services, the rationale for the marked variations in fees within specialties is unknown. As insurers are prohibited from providing cover for the costs of outpatient care, the impact of out-of-pocket payments on access to private specialist care is unknown.
PMID: 28253468 [PubMed - in process]
Source: Medical Journal of Australia - March 3, 2017 Category: Journals (General) Tags: Med J Aust Source Type: research
